HALOZYME THERAPEUTICS, INC.
No SEC Form 4 filings for $HALO in the last 30 days.
Halozyme Therapeutics (NASDAQ: HALO) shares rose about 20% after the company reported Q2 adjusted EPS of $2.28 and revenue of $481 million, both above analyst estimates, and raised full-year guidance. The company lifted revenue guidance to a $1.87 billion midpoint and adjusted EPS to $8.83 midpoint, citing ENHANZE royalties and milestones.
Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.
U.S. July payrolls contracted, with 23,000 jobs lost versus 80,000 forecast, and May-June payrolls revised down by 103,000. Hourly earnings rose 0.1% monthly and 3.2% yearly. Fed rate-hike odds for September fell to 42%. Stocks hit records; Atlassian (+30.8%), Twilio (+30.6%), and Trade Desk (-21%) moved on earnings.
Over the past 7 days, alphai's AI scored 8 news stories mentioning HALO (HALOZYME THERAPEUTICS, INC.). Coverage has skewed bullish: 8 bullish, 0 neutral, and 0 bearish.
Recent HALO coverage spans earnings, market movers and macro economy.
Earnings beat plus upward guidance is likely to sustain bullish momentum and re-rate near-term expectations for ENHANZE royalty growth.
Upgraded outlook tied to Enhanze licensing and royalty growth expectations likely sustains upside sentiment.
Raised outlook with strong growth supports sustained estimate-upward revisions.
The beat-and-raise plus capital return signals likely supports near-term upside and raises the bar for subsequent quarters.
The earnings beat plus broad-based guidance raise and partnership momentum are likely to sustain near-term upside and compress downside risk.
alphai scores every news story that mentions HALO with an AI model for sentiment and relevance, and aggregates insider trades from HALOZYME THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Halozyme Therapeutics (NASDAQ: HALO) shares rose about 20% after the company reported Q2 adjusted EPS of $2.28 and revenue of $481 million, both above analyst estimates, and raised full-year guidance. The company lifted revenue guidance to a $1.87 billion midpoint and adjusted EPS to $8.83 midpoint, citing ENHANZE royalties and milestones.
4 min readNatera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.
6 min readU.S. July payrolls contracted, with 23,000 jobs lost versus 80,000 forecast, and May-June payrolls revised down by 103,000. Hourly earnings rose 0.1% monthly and 3.2% yearly. Fed rate-hike odds for September fell to 42%. Stocks hit records; Atlassian (+30.8%), Twilio (+30.6%), and Trade Desk (-21%) moved on earnings.
7 min readHalozyme Therapeutics (HALO) shares rose about 15% after the company reported record Q2 2026 results and raised 2026 guidance, according to Halozyme’s investor release. Q2 total revenue increased 48% to $481 million, royalty revenue rose 50% to $307.7 million. Full-year 2026 revenue guidance was raised to $1.835B-$1.910B and non-GAAP diluted EPS to $8.65-$9.00.
4 min readHalozyme Therapeutics shares rose about 6.1% pre-open after the company reported record Q2 2026 results. Total revenue increased 48% to $481 million and non-GAAP EPS was $2.28, both above expectations. Royalty revenue hit $307.7 million. Halozyme raised full-year 2026 guidance to non-GAAP EPS of $8.65-$9.00 and revenue of $1.835-$1.910 billion, and said it signed five new ENHANZE/Hypercon deals year-to-date.
2 min readHalozyme Therapeutics (NASDAQ:HALO) reported Q2 royalty momentum for VYVGART Hytrulo, with royalty revenue up 143% to $72.6M and total VYVGART brand sales up 60% to $1.5B. Other royalty revenue rose 85% to $54.4M. Halozyme raised 2026 guidance to $1.835B-$1.91B revenue and $8.65-$9.00 non-GAAP EPS, and repurchased $332.8M of stock.
6 min readHalozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 revenue of $481 million, up 47.7% year over year, beating Wall Street estimates. The company guided full-year revenue to $1.87 billion at the midpoint, 5.9% above consensus, and posted non-GAAP EPS of $2.28, 25.5% above estimates, according to the company.
3 min readHALOZYME THERAPEUTICS, INC. (HALO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q220268-k.htm EX-99.1 Document Exhibit 99.1 HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 20
6 min readBiotech stocks hit 52-week highs on July 24, 2026, including Inhibikase Therapeutics (IKT) at $2.53 after FDA orphan drug designation for IKT-001 and Phase 3 IMPROVE-PAH progress. Jazz Pharmaceuticals (JAZZ) reached $256.75, with Q1 2026 revenue up 19% to $1.1B. Halozyme (HALO) hit $82.99, Q1 revenue $376M (+42%). Corcept (CORT) rose to $97.63, Q1 revenue $164M. Liquidia (LQDA) reached $91.10 on YUTREPIA revenue and net income.
4 min readThe article reviews pharma news. Halozyme Therapeutics said it signed a licensing deal with Incyte for INCA033989. Samsung Biologics plans to buy Swiss firm PolyPeptide for about $1.8 billion. Celldex reported mixed barzolvolimab results in prurigo nodularis and will stop that program. Sanofi will discontinue amlitelimab development in atopic dermatitis.
6 min read
